Table 2 The relationship between Sirius Red staining and CRC clinicopathological features
| Â | No. of cases | Low | Medium | High | x2 value | P-value |
|---|---|---|---|---|---|---|
Frequency | 88 (100%) | 38 (43.2%) | 28 (31.8%) | 22 (25%) | Â | Â |
Age | ||||||
  < 60 years | 40 (45.5%) | 16 (40.0%) | 12 (30.0%) | 12 (30.0%) | 0.981 | 0.612 |
  >  = 60 years | 48 (54.5%) | 22 (45.8%) | 16 (33.3%) | 10 (20.8%) |  |  |
Gender | ||||||
 Male | 51 (58.0%) | 22 (43.1%) | 17 (33.3%) | 12 (23.5%) | 0.193 | 0.908 |
 Female | 37 (42.0%) | 22 (43.2%) | 42 (29.7%) | 12 (27.0%) |  |  |
Position | ||||||
 Colon | 57 (64.8%) | 21 (36.8%) | 20 (35.1%) | 16 (28.1%) | 4.218 | 0.377 |
 Rectum | 27 (30.7%) | 15 (55.6%) | 6 (22.2%) | 6 (22.2%) |  |  |
 Colorectum | 4 (4.5%) | 2 (50.0%) | 2 (50.0%) | 0 (0.0%) |  |  |
Tumor size(maximum diameter) | ||||||
  < 5 cm | 46 (52.3%) | 17 (37.0%) | 18 (39.1%) | 11 (23.9%) | 2.530 | 0.282 |
 >  = 5 cm | 42 (47.7%) | 21 (50.0%) | 10 (23.8%) | 11 (26.2%) |  |  |
Histology | ||||||
 Poor | 13 (14.8%) | 6 (46.2%) | 2 (15.4%) | 5 (38.5%) | 5.948 | 0.203 |
 Moderate | 65 (73.9%) | 25 (38.5%) | 24 (36.9%) | 16 (24.6%) |  |  |
 Well | 10 (11.4%) | 7 (70.0%) | 2 (20.0%) | 1 (10.0%) |  |  |
T stage | ||||||
 Tis | 1 (1.1%) | 1 (100.0%) | 0 (0.0%) | 0 (0.0%) | 19.325 | 0.013 |
 T1 | 3 (3.4%) | 3 (100.0%) | 0 (0.0%) | 0 (0.0%) |  |  |
 T2 | 12 (13.6%) | 10 (83.3%) | 2 (16.7%) | 0 (0.0%) |  |  |
 T3 | 57 (64.8%) | 21 (36.8%) | 21 (36.8%) | 15 (26.3%) |  |  |
 T4 | 15 (17.0%) | 3 (20.0%) | 5 (33.3%) | 7 (46.7%) |  |  |
Tumor budding | ||||||
 Bd1 | 45 (51.1%) | 26 (57.8%) | 10 (22.2%) | 9 (20.0%) | 10.351 | 0.035 |
 Bd2 | 29 (33.0%) | 10 (34.5%) | 12 (41.4%) | 7 (24.1%) |  |  |
 Bd3 | 14 (15.9%) | 2 (14.3%) | 6 (42.9%) | 6 (42.9%) |  |  |
Lymphatic metastasis | ||||||
 Negative | 48 (54.5%) | 28 (58.3%) | 13 (27.1%) | 7 (14.6%) | 10.941 | 0.004 |
 Positive | 40 (45.5%) | 10 (25.0%) | 15 (37.5%) | 15 (37.5%) |  |  |
Tumor deposits | ||||||
 Absent | 75 (85.2%) | 36 (48.0%) | 24 (32.0%) | 15 (20.0%) | 7.812 | 0.020 |
 Present | 13 (14.8%) | 2 (15.4%) | 4 (30.8%) | 7 (53.8%) |  |  |
Mucinous component | ||||||
 Absent | 17 (19.3%) | 7 (41.2%) | 5 (29.4%) | 5 (29.4%) | 0.222 | 0.895 |
 Present | 71 (80.7%) | 31 (43.7%) | 23 (32.4%) | 17 (23.9%) |  |  |
Distant metastasis | ||||||
 Negative | 85 (96.6%) | 37 (43.5%) | 27 (31.8%) | 21 (24.7%) | 0.158 | 0.924 |
 Positive | 3 (3.4%) | 1 (33.3%) | 1 (33.3%) | 1 (33.3%) |  |  |
Microstatellite instability | ||||||
 MSS | 71 (80.7%) | 28 (39.4%) | 24 (33.8%) | 19 (26.8%) | 4.258 | 0.372 |
 MSI-L | 7 (8.0%) | 3 (42.9%) | 3 (42.9%) | 1 (14.3%) |  |  |
 MSI-H | 10 (11.4%) | 7 (70.0%) | 1 (10.0%) | 2 (20.0%) |  |  |
Neoadjuvant chemotherapy | ||||||
 Negative | 87 (98.9%) | 38 (32.8%) | 28 (48.4%) | 21 (18.8%) | 3.034 | 0.219 |
 Positive | 1 (1.1%) | 0 (44.4%) | 0 (22.2%) | 1 (33.3%) |  |  |
TNM stage | ||||||
 0 | 2 (2.3%) | 2(100.0%) | 0 (0.0%) | 0 (0.0%) | 20.396 | 0.009 |
 I | 10 (11.4%) | 9 (90.0%) | 1 (10.0%) | 0 (0.0%) |  |  |
 II | 31 (35.2%) | 16 (51.6%) | 10 (32.3%) | 5 (16.1%) |  |  |
 III | 42 (47.7%) | 10 (23.8%) | 16 (38.1%) | 16 (38.1%) |  |  |
 IV | 3 (3.4%) | 1 (33.3%) | 1 (33.3%) | 1 (33.3%) |  |  |